Summary of Significant Accounting Policies - Net Product Revenues by Product (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended									12 Months Ended
	Dec. 31, 2014		Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Net product revenues	$ 13,477	[1]	$ 341,547	$ 375,539	$ 402,979	$ 237,555	$ 238,184	$ 235,441	$ 202,601	$ 1,133,542	$ 913,781	$ 735,444
Xifaxan [Member]
Segment Reporting Information [Line Items]
Net product revenues										405,442	635,941	514,480
Inflammatory Bowel Disease-Apriso/Uceris/Giazo/Colazal [Member]
Segment Reporting Information [Line Items]
Net product revenues										227,083	117,914	85,504
Diabetes-Glumetza/Cycloset [Member]
Segment Reporting Information [Line Items]
Net product revenues										308,085
Purgatives-OsmoPrep/MoviPrep [Member]
Segment Reporting Information [Line Items]
Net product revenues										11,380	76,390	64,932
Zegerid [Member]
Segment Reporting Information [Line Items]
Net product revenues										112,644
Other-Anusol/Azasan/Diuril/Pepcid/Proctocort/Relistor/Deflux/Solesta/Fulyzaq/Metozolv
Segment Reporting Information [Line Items]
Net product revenues										$ 68,908	$ 83,536	$ 70,528

[1] Net product revenue in the fourth quarter of 2014 reflects the Company’s determination to substantially cease all sales efforts to wholesalers and sell only minimal amounts of its products during the fourth quarter in furtherance of the Company’s previously announced accelerated inventory reduction plan.